Loading clinical trials...
Loading clinical trials...
A Phase I Study of PI3Kα,δ Inhibitor Copanlisib in Combination With PD-1 Antagonist Nivolumab in Patients With Transformed Chronic Lymphocytic Leukemia (Richter's Transformation) or Non-Hodgkin Lymphoma
Conditions
Interventions
Copanlisib
Nivolumab
Locations
3
United States
City of Hope Medical Center
Duarte, California, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
OHSU Knight Cancer Institute
Portland, Oregon, United States
Start Date
February 26, 2019
Primary Completion Date
November 4, 2026
Completion Date
November 4, 2026
Last Updated
December 30, 2025
NCT07545603
NCT06846671
NCT07218341
NCT06548152
NCT06149286
NCT05272384
Lead Sponsor
City of Hope Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions